The magnitude of the revenue decline (52% YoY) and the second consecutive guidance cut this year signal deteriorating fundamentals beyond the timing-driven MCM lumpiness. Monitor Q4 2026 for the pace of USG contract awards and whether the naloxone decline stabilizes; the CFO transition adds execution risk to the turnaround plan.
Drugs in focus
EBS drug pipeline →ACAM2000
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed since 2007 (smallpox) and 2024 (mpox).
- Next catalyst
- None dated
What to watchACAM2000 is an approved, revenue-generating product with no pending FDA binary catalyst. Watch for U.S. government contract option exercises (the 10-year ASPR deal has annual renewals) and further international approvals, which drive lumpy quarterly revenue. The Q3 2026 revenue miss and lowered guidance are the near-term headwind to watch.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $6.25entry
- T+1 · 13d ago −5.60%α −7.25% · $5.90
- T+5 · 7d ago −3.20%α −2.61% · $6.05
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Emergent BioSolutions reported Q3 2026 total revenue of $110.0M, down 52% YoY from $231.1M, and a GAAP net loss of $32.7M versus net income of $51.2M in Q3 2025. Revenue was within the company's prior guidance range but missed the consensus estimate of $123.2M. The company lowered its full-year 2026 revenue guidance to $600M-$645M from $645M-$675M and its adjusted EBITDA guidance to $110M-$140M from $130M-$150M, citing timing of USG and international MCM sales and a 20%-25% YoY decline in commercial (naloxone) revenues.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue of $110.0M, down 52% YoY from $231.1M, missing consensus of $123.2M
- GAAP net loss of $32.7M vs net income of $51.2M in Q3 2025; GAAP diluted EPS of ($0.64) vs $0.91
- Adjusted net loss of $18.7M vs adjusted net income of $65.2M in Q3 2025
- Adjusted EBITDA of ($4.6M) vs $92.6M in Q3 2025; adjusted EBITDA margin of (4)% vs 40%
- Full-year 2026 revenue guidance lowered to $600M-$645M from $645M-$675M
- Full-year 2026 adjusted EBITDA guidance lowered to $110M-$140M from $130M-$150M
- Naloxone revenue fell 42% YoY to $43.5M; Smallpox MCM revenue fell 68% YoY to $26.7M; Other Products (BAT) fell 87% YoY to $7.6M
- CFO Rich Lindahl announced retirement effective Dec 31, 2026; Frank Vargo to serve as interim CFO
- Completed repurchase of $75M aggregate principal of Senior Unsecured Notes in Q3
- Implemented restructuring in August 2026; incurred $8M of restructuring costs in Q3
Financial Impact
Revenue miss of ~$13.2M vs consensus; full-year revenue guidance cut by $45M at midpoint; adjusted EBITDA guidance cut by $30M at midpoint; Q3 adjusted EBITDA swung from +$92.6M to -$4.6M YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Commercial Products (Naloxone) | $43.5M | -42.0% |
| MCM Products | $59.4M | -58.0% |
Risk Factors
- Continued erosion of naloxone revenue due to generic competition and unfavorable price/volume mix
- Lumpy USG and international MCM procurement timing creates unpredictable quarterly revenue swings
- CFO retirement and interim CFO appointment introduces leadership uncertainty during restructuring
- Full-year net loss forecast of $(255M)-$(225M) reflects $191M non-cash impairment charge in Q2 2026
- Net leverage increased to 2.4x from 1.9x YoY despite debt reduction, due to lower trailing EBITDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001367644-26-000110 |
| Document: ebs2026-09x30deckfinal.htm | 0001367644-26-000110 |
| Document: ebs-20261102.htm | 0001367644-26-000110 |
| Document: 0001367644-26-000110-index-headers.html | 0001367644-26-000110 |
| Document: 0001367644-26-000110-index.html | 0001367644-26-000110 |
| Document: 0001367644-26-000110.txt | 0001367644-26-000110 |
| 8-K Data (Synthetic) | 0001367644-26-000110 |
Track record
23 reports on EBS
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Viewing Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
- Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
- Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers